Douglas Dieterich, MD

Articles by Douglas Dieterich, MD

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

ByZobair Younossi, MD,Stuart C. Gordon, MD,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD,Rachel Beckerman, PhD

February 16th 2017

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

ByZobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD,Haesuk Park, PhD,Stuart C. Gordon, MD,John R. Ferguson,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD, MPH

May 3rd 2016

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

Latest Updated Articles

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C
May 3rd 2016
Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
February 16th 2017

Douglas Dieterich, MD

Articles by Douglas Dieterich, MD

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

Latest Updated Articles

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care